Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO)

Protein degradation can begin as soon as cells or tissues are disrupted. Delayed processing, warm samples, incomplete inhibitor coverage, or an inhibitor that is incompatible with the downstream assay can reduce recovery of intact targets and alter apparent protein abundance. The Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO) is intended to address this problem during extraction and related protease-sensitive workflows.

The formulation contains AEBSF, Aprotinin, Bestatin, E-64, Leupeptin, and Pepstatin A. Together, these components provide coverage against serine proteases, cysteine proteases, acid proteases, and aminopeptidases. Because the formulation is EDTA-free, it can be considered when divalent cations must remain available for phosphorylation analysis, kinase assays, or other enzyme-dependent measurements.

What This Product Solves

This product is primarily a protein extraction protease inhibitor for preserving sample composition between lysis and analysis. It is useful when the experimental objective depends on detecting intact proteins, complexes, post-translationally modified species, or native enzyme activity. A broad inhibitor mixture is often preferable to relying on a single serine protease inhibitor when the protease profile of a sample is not fully defined.

For Western blotting, limiting proteolysis helps reduce loss or fragmentation of the target band. In co-immunoprecipitation and pull-down assays, protecting both bait and prey proteins can support recovery of complexes that are otherwise vulnerable during lysis and washing. The same principle applies to immunofluorescence, immunohistochemistry, and other procedures in which proteolysis can compromise antigen integrity.

The EDTA-free design is an important selection criterion rather than a minor formulation detail. EDTA-containing cocktails can chelate divalent cations and may interfere with metal-dependent enzymes, phosphorylation-related measurements, or assays that require calcium or magnesium. This product does not replace EDTA when deliberate metal-ion chelation is part of the method.

A related protein extraction overview provides additional context on degradation control; it complements this article by focusing more broadly on extraction-stage preservation. A separate laboratory use guide discusses practical use of the EDTA-free formulation and its compatibility boundaries.

Protocol Parameters

Use the following parameters as a starting framework. Product-dossier values are separated from workflow recommendations so that assay-specific optimization is not mistaken for a product specification.

• Assay: Protein extraction; Value: dilute the 200X stock at least 200-fold for use; Applicability: cell, tissue, and other lysate preparation; Rationale: establishes the intended working dilution for broad protease coverage; Evidence classification: product specification.
• Assay: Cell-culture treatment; Value: effective in culture medium for up to 48 hours, followed by medium replacement; Applicability: workflows using inhibitor-containing culture medium; Rationale: limits the duration of use of the prepared medium; Evidence classification: product specification.
• Assay: Storage of the concentrated cocktail; Value: -20 °C; stable for at least 12 months under this condition; Applicability: unopened or appropriately handled stock storage; Rationale: preserves the supplied concentrate during the stated storage period; Evidence classification: product specification.
• Assay: Phosphorylation-sensitive or divalent-cation-dependent assay; Value: use the EDTA-free formulation and verify the final cocktail concentration in a pilot; Applicability: kinase assays, enzyme assays, and phosphorylation analysis; Rationale: avoids adding EDTA while checking for assay-specific effects from the inhibitor mixture or DMSO vehicle; Evidence classification: workflow recommendation.
• Assay: Sensitive cell line; Value: begin at the required minimum dilution and test further dilution if needed; Applicability: live-cell exposure or culture-medium applications; Rationale: the dossier specifies adjustment according to cell-line sensitivity; Evidence classification: product specification with workflow optimization.

Workflow Setup and QC Checklist

Before lysis or treatment

• Confirm that the experiment requires protease suppression and that EDTA is not needed for the intended assay. If metal chelation is a deliberate part of the method, select an appropriate EDTA-containing strategy instead.
• Thaw and mix the concentrated stock according to the laboratory's controlled handling procedure. Prepare only the amount needed for the experiment when possible, and document stock identification, dilution, and preparation time.
• Prepare the working solution in the compatible lysis buffer or culture medium. For extraction, add the diluted cocktail before or at the time of sample disruption so that proteases are inhibited as early as practical.
• For cell culture, include a matched vehicle control when DMSO exposure could affect viability, morphology, signaling, or the assay readout. Confirm cell-line tolerance before extending exposure.

During extraction

• Keep samples cold and minimize the interval between lysis, clarification, and loading or binding. The cocktail supports protein degradation prevention but does not compensate for prolonged warm handling or repeated processing delays.
• Use the same inhibitor dilution, lysis ratio, incubation conditions, and clarification procedure across compared samples. Inconsistent treatment can appear as biological variation in Western blot or co-immunoprecipitation experiments.
• For phosphorylation analysis or enzyme assays, include a matrix or process control that confirms the inhibitor-containing lysate does not alter the specific readout. EDTA-free status reduces one compatibility concern but does not prove universal assay compatibility.

QC checks

Record whether the stock was stored at -20 °C, the working dilution used, the time of addition, and the time from lysis to analysis. A small side-by-side comparison with and without the cocktail can establish whether degradation is a meaningful source of variation for the specific sample type. For culture applications, record the medium-change schedule and replace inhibitor-containing medium within the stated 48-hour period.

Common Failure Modes and Fixes

Target bands remain fragmented or weak

Possible causes include adding inhibitor after a long lysis interval, inadequate sample cooling, excessive mechanical disruption, or incomplete mixing. Add the diluted cocktail before disruption, shorten handling time, and standardize clarification. If degradation persists, test the sample with the recommended working dilution and review whether the target protease activity may fall outside the listed inhibitor coverage.

Cells show reduced viability or altered morphology

Cell-line sensitivity, DMSO exposure, or prolonged treatment may contribute. Compare with a vehicle-matched control, confirm the dilution calculation, and evaluate a further dilution when compatible with the preservation objective. For culture-medium use, do not continue the same prepared medium beyond the stated 48-hour period without replacement.

Kinase or enzyme assay results are inconsistent

Although the formulation is EDTA-free, individual inhibitor components and the DMSO vehicle can still affect a sensitive assay matrix. Use a no-inhibitor control, a vehicle control where appropriate, and a matrix-matched positive control. Avoid interpreting a single failed assay as evidence that all enzyme workflows are incompatible.

Co-immunoprecipitation recovery is poor

Low recovery may result from harsh lysis conditions, excessive detergent, antibody incompatibility, or loss of binding during washing rather than proteolysis alone. Keep the inhibitor concentration and lysis chemistry constant between samples, and separately optimize detergent, salt, incubation, and wash conditions.

Scope and Limitations

No directly matched paper evidence for SKU K1008 was supplied, so the guidance here is limited to the product dossier and standard laboratory workflow practices. It should not be presented as a published head-to-head comparison, a quantitative performance guarantee, or evidence that every protein or protease is equally protected.

The cocktail is broad-spectrum within the inhibitor classes represented by AEBSF, Aprotinin, Bestatin, E-64, Leupeptin, and Pepstatin A, but it is not a universal solution for every degradation mechanism. It also does not replace rapid processing, cold handling, suitable lysis chemistry, or assay-specific controls. The 200X stock is supplied in DMSO, so solvent effects must be considered in live-cell and biochemical assays. Storage stability of at least 12 months applies to the stated -20 °C condition and should not be extrapolated to untested storage or repeated handling conditions.

Conclusion

Use this EDTA-free Protease Inhibitor Cocktail when broad protease coverage is needed during extraction or protease-sensitive analysis without intentionally chelating divalent cations. Dilute the DMSO stock at least 200-fold, add it early in the workflow, keep samples cold, document handling, and validate the final condition with assay-appropriate controls. These steps make the product a practical Western blot protease inhibitor and co-immunoprecipitation protease inhibitor while maintaining clear boundaries for cell culture and enzyme-based applications.